Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER_GOV 1OTHER 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 67Neoplasm Metastasis 6Prostatic Neoplasms, Castration-Resistant 5Non-metastatic Castration-resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer 4Prostatic Diseases 3Adenocarcinoma 3Urogenital Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Hormone-sensitive Prostate Cancer 2Male Urogenital Diseases 2Genital Diseases, Male 2Biochemically Recurrent Prostate Cancer 2Urogenital Diseases 1Thrombocytosis 1Sleep Initiation and Maintenance Disorders 1Prostate Cancer Non-Metastatic 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-metastatic Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

pembrolizumab 6Radiosurgery 5Docetaxel 5enzalutamide 4darolutamide 3Radiotherapy 3Everolimus 3Androgen Antagonists 3relugolix 2luprolide acetate gel depot 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Image-Guided 2Radiofrequency Ablation 2Panobinostat 2Leuprolide 2Abiraterone Acetate 2trastuzumab deruxtecan 1talazoparib 1spartalizumab 1siremadlin 1sipuleucel-T 1sargramostim 1resiquimod 1polysaccharide-K 1poly ICLC 1palbociclib 1olaparib 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × darolutamide × Genitourinary × Clear all
NCT07617272 2026-06-01

PARIS-BIO

Region Stockholm

Phase 2 Recruiting
100 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth

Phase 1 Recruiting
30 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡